Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT4I2W)

• Drug Name: Aom-0890 Drug Info
• Synonyms: Aom-0891; PDE5 inhibitors (oral/tablet, erectile dysfunction); PDE5 inhibitors (oral/tablet, erectile dysfunction), Hangzhou Adamerck

Indication

Disease Entry	ICD 11	Status	REF
Erectile dysfunction	HA01.1	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMT4I2W

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Benign prostatic hyperplasia	GA90	Approved	[2]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[3]
Vardenafil	DMTBGW8	Cystic fibrosis	CA25	Approved	[4]
Dipyridamole	DMXY30O	Atrial fibrillation	BC81.3	Approved	[5]
Papaverine	DMCA9QP	Brain ischaemia	8B1Z	Approved	[6]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[7]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[8]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[9]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[10]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[1]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
• [2] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [3] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [4] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [5] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [6] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [9] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [10] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [11] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.